BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study.

ABSTRACT:

Objectives

PARP inhibitors (PARPi) have become the new standard maintenance treatment for patients with advanced homologous recombination deficiency (HRD) ovarian cancer; they are also used upon platinum-sensitive relapse. HRD in ovarian cancer is primarily assessed through BRCA genes mutations and genomic scar scores, which are key biomarkers forecasting PARPi benefit. However, the role of BRCA1 promoter methylation in guiding clinical management is unclear. Evidence is needed to improve patient selection before initiating PARPi and to minimize PARPi-related toxicities. Our study aimed to determine the clinical relevance of BRCA1 promoter methylation for patients with ovarian carcinoma.

Method

The KOMET (Ovarian Cancer Methylation) study is a single-center retrospective stu

SUBMITTER: Nougarede L 

PROVIDER: S-EPMC12329904 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature